Last reviewed · How we verify
Direct Acting Antivirals
Direct-acting antivirals inhibit viral enzymes or proteins required for viral replication, preventing the virus from multiplying within host cells.
Direct-acting antivirals inhibit viral enzymes or proteins required for viral replication, preventing the virus from multiplying within host cells. Used for Hepatitis C virus (HCV) infection, Potentially other viral infections depending on specific agent.
At a glance
| Generic name | Direct Acting Antivirals |
|---|---|
| Also known as | DAAs in Non Cirrhotics, Sofosbuvir, Daclatasvir, Ledipasvir, Direct Acting Antiviral HCV Treatment |
| Sponsor | Medical University of Warsaw |
| Drug class | Direct-acting antiviral (DAA) |
| Modality | Small molecule |
| Therapeutic area | Virology/Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
DAAs work by directly targeting and blocking specific viral proteins such as proteases, polymerases, or other essential enzymes needed for the viral life cycle. This class is most well-established for hepatitis C virus (HCV) treatment, where combinations of DAAs targeting different viral proteins have achieved cure rates exceeding 95%. The mechanism differs from older interferon-based therapies by directly interfering with viral replication machinery rather than boosting immune response.
Approved indications
- Hepatitis C virus (HCV) infection
- Potentially other viral infections depending on specific agent
Common side effects
- Headache
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents (PHASE4)
- First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics (PHASE1)
- HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots
- OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial (PHASE2)
- OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients (PHASE2)
- Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients (NA)
- Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients (PHASE2)
- Predictors of HCC in Post-HCV Cirrhotic Patients After SVR
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Direct Acting Antivirals CI brief — competitive landscape report
- Direct Acting Antivirals updates RSS · CI watch RSS
- Medical University of Warsaw portfolio CI